Which structural feature of mycobacteria most directly explains the need for prolonged, multidrug therapy?
Choose an answer, then check it.
Clinical Pharmacology · Antibacterial Medications
Antimycobacterial Medications
On this page 6 sections
In 30 seconds
Mycobacteria have a waxy, mycolic-acid cell wall and grow slowly, hiding both inside macrophages and in dormant pockets that ordinary antibiotics cannot reach. Treating tuberculosis therefore always means combining several drugs for an extended course, never a single agent for a short one. The core regimen — rifampin, isoniazid, pyrazinamide, and ethambutol (RIPE) — kills fast- and slow-growing organisms alike while guarding against resistance. Skipping doses is the single biggest driver of drug-resistant TB, which is why adherence support and monitoring dominate the nursing role here.
The college version
Why Mycobacteria Need Special Treatment
Mycobacterium tuberculosis and its relatives are wrapped in a thick, lipid-rich wall built from mycolic acids. This wall is nearly impermeable to many standard antibiotics, resists drying and acid (hence "acid-fast" staining), and lets the organism survive for long periods inside host macrophages, shielded from immune attack and from drugs that cannot penetrate cells. Populations of bacilli also exist in different metabolic states within the same patient — some multiplying rapidly in cavitary lesions, others nearly dormant in old granulomas. No single drug kills all these subpopulations, and any single agent used alone allows resistant mutants to be selected out. These features explain why therapy always uses multiple drugs together and continues for many months, structured in an initial intensive phase to rapidly reduce the actively dividing population, followed by a longer continuation phase to eliminate slower-growing and residual organisms.
First-Line Agents (RIPE)
Rifampin is a potent inducer of hepatic CYP450 enzymes, accelerating metabolism of many co-administered drugs including oral contraceptives, warfarin, and some antiretrovirals; it also causes harmless orange-red discoloration of urine, sweat, tears, and contact lenses, and carries a risk of hepatotoxicity.
Isoniazid (INH) is a cornerstone agent whose chief risks are hepatotoxicity and peripheral neuropathy. The neuropathy results from isoniazid interfering with vitamin B6 (pyridoxine) metabolism, so pyridoxine supplementation is routinely given alongside it to prevent this. Patients metabolize isoniazid at genetically variable rates — "slow acetylators" clear the drug more gradually and accumulate higher levels, raising toxicity risk, while "fast acetylators" clear it quickly, which can affect efficacy and dosing considerations.
Pyrazinamide contributes strong sterilizing activity, especially against dormant organisms in acidic intracellular environments, but is associated with hepatotoxicity and with hyperuricemia that can precipitate gout.
Ethambutol carries a distinctive dose-related risk of optic neuritis, presenting as decreased visual acuity and loss of red-green color discrimination. Baseline and periodic eye examinations, along with patient reporting of visual changes, are essential safeguards.
Monitoring and Counseling
Because several first-line drugs share hepatotoxic potential, baseline and periodic liver enzyme checks are standard, and patients are counseled to recognize hepatitis warning signs — unexplained fatigue, nausea, dark urine, jaundice — and to avoid or minimize alcohol, which compounds hepatic risk. Ethambutol therapy adds ongoing visual monitoring.
Adherence and Drug Resistance
Because therapy is long and multidrug, incomplete adherence is the central threat: missed or partial dosing allows resistant organisms to survive and multiply, producing multidrug-resistant TB (resistant to at least isoniazid and rifampin) or extensively drug-resistant TB (resistant to additional key agents). Directly observed therapy, in which a healthcare worker watches each dose being taken, is a cornerstone strategy for preventing this outcome and is used widely for active disease. When resistance does develop, second-line agents are required, generally including fluoroquinolones, bedaquiline, linezolid, and, less commonly now, injectable agents — regimens that tend to be longer, less well tolerated, and less effective than first-line therapy.
Latent Infection, MAC, and Leprosy
Latent tuberculosis infection — inactive, asymptomatic infection with a positive screening test but no active disease — is treated with a shorter regimen using fewer drugs than active disease, since the bacterial burden is far lower. Treating latent infection prevents future progression to active, transmissible disease. Mycobacterium avium complex (MAC), an opportunistic infection most relevant in significantly immunocompromised patients, is treated with a distinct multidrug combination rather than standard TB drugs. Leprosy (Hansen disease) uses its own multidrug regimen, typically combining dapsone, clofazimine, and rifampin, chosen to prevent resistance and shorten the long natural course of treatment.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine a germ that builds itself a thick, waxy raincoat and then hides inside your own body's cells like it's ducking into a fort. Regular antibiotics slide right off that raincoat, and even if one gets through, some of the germs are basically "asleep" and barely doing anything, so the medicine can't catch them mid-action. That is why TB treatment always uses a team of different medicines at once — each one attacks the germ in a different way, so no matter which "mode" a germ is in, something is coming after it. The team also has to stay on the job for a long time, because sleepy germs wake up slowly. Each medicine has its own side effect to watch for: one turns your pee orange, one can hurt your liver, one can make a nerve tingly (so you take a vitamin to protect it), one can make your big toe joint hurt, and one can blur your eyesight if the dose is too strong. If someone stops taking their medicine team too early, the toughest germs survive and multiply, becoming super-germs that are much harder to treat later. That is why nurses sometimes watch patients swallow every single dose, like a coach making sure a player does every rep.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with active TB frequently misses scheduled doses of their multidrug regimen. Explain the specific risk this creates and one strategy used to prevent it.
Show answer
Missed doses let the toughest germs survive and become drug-resistant.
Skipping doses lets partially-treated, hardier bacteria survive and multiply, which can produce multidrug-resistant or extensively drug-resistant TB; directly observed therapy, where a provider watches the patient take each dose, helps ensure completion and prevent this.
A patient asks why their latent TB infection treatment involves fewer drugs and a shorter course than their coworker's active TB treatment. Explain the reason for this difference.
Show answer
Latent infection means far fewer germs are present, so less firepower is needed.
In latent TB the bacteria are inactive and present in tiny numbers, unlike the large, actively multiplying population in active disease, so a shorter course with fewer drugs is enough to clear it and prevent future active disease.
Quick check
3 questions here. Answers stay hidden until you check.
A patient on isoniazid reports tingling and numbness in both feet. Which co-administered supplement is intended to prevent this?
Choose an answer, then check it.
Which first-line agent requires baseline and periodic visual acuity and color discrimination testing?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.